PapersPMID:38836372
Efficacy of astragalus combined with renin-angiotensin-aldosterone system blockers in the treatment of stage III diabetic nephropathy: a systematic review and meta-analysis.
- findings
- 2
- compound
- 1
- endpoints
- 2
- Study, every finding
- meta-analysis
- Dose studied, every finding
- Pooled; astragalus injection 20 to 60 mL per day or oral astragalus 20 to 180 g per day, added to an ACE inhibitor or ARB, 1 to 48 weeks
What moved
How to read these marks →“During the treatment period, the total effective rate of the astragalus-RAAS blocker combination group was markedly higher than that of the RAAS blocker group (odds ratio [OR] = 3.63, 95% CI [2.59, 5.09], p < 0.00001; Figure 2).”
- Effect
- 3.63 odds ratio, 95% CI 2.59 to 5.09
- Population
- Adults with stage III diabetic nephropathy (Mogensen staging); 14 pooled Chinese trials in which both arms received the same ACE inhibitor or ARB and only one arm also received astragalus; routes pooled (injection and oral herb)
- Decreases fasting blood glucose
moderate
“The Astragalus combined RAAS blocker therapy showed a significantly larger decrease in FPG compared with the control group (WMD: −0.28, 95% CI [−0.40, −0.17], p < 0.00001; Figure 7).”
- Effect
- −0.28 mean difference, 95% CI −0.4 to −0.17
- Population
- Adults with stage III diabetic nephropathy (Mogensen staging); 15 pooled Chinese trials in which both arms received the same ACE inhibitor or ARB and only one arm also received astragalus; routes pooled (injection and oral herb)
Study record
- Design
- meta-analysis
- Species
- human
- Population
- Patients with stage III diabetic nephropathy (Mogensen staging), all receiving a RAAS blocker (ACEI or ARB), in 32 Chinese RCTs
- Participants
- 2,462
- Comparator
- no treatment
- Duration
- not reported
- Endpoints measured
- 22